8-K: Soligenix SGX945 Demonstrates Biological Efficacy in Behet's Disease Phase 2a Study

Soligenix, Inc. announced positive Phase 2a proof of concept study results for SGX945 (dusquetide) in treating Behet's Disease, showing biological efficacy and favorable comparison to apremilast.

Summary

• Soligenix completed its Phase 2a proof of concept study for SGX945 (dusquetide) in Behet's Disease, achieving the objective of demonstrating biological efficacy.
• The study was open-label and designed to be comparable to the published Phase 3 study of apremilast (Otezla), with SGX945 outcomes compared to both apremilast and placebo arms.
• After 4 weeks of treatment, SGX945 showed a 40% improvement in the area under the curve (AUC) of mean oral ulcers relative to the placebo group from the apremilast study, compared to apremilast's 37% improvement.
• This improvement with SGX945 was sustained, showing a 32% improvement at Week 8 despite treatment stopping at Week 4, while continuously administered apremilast had a 41% improvement at Week 8.
• Improvements in oral pain with SGX945 mimicked the AUC results.
• Seven of eight patients reported perceived benefit from SGX945 treatment, including reduced duration and number of oral ulcers, and reduced oral pain.
• One patient's punctuated skin ulcer, generally difficult to resolve, also resolved during the 4-week SGX945 treatment.
• SGX945 was well-tolerated with no treatment-related adverse events, unlike apremilast which commonly caused diarrhea (41%), nausea (19%), and headache (14%).
• Behet's Disease is an incurable, chronic inflammatory disorder affecting up to 18,000 people in the U.S. and 1 million worldwide, with significant unmet medical need, especially for severe ulcers.

Sentiment

Score: 9

Explanation: The filing presents highly positive clinical trial results for SGX945, demonstrating biological efficacy, superior initial performance compared to the only approved competitor, a significantly better safety profile, and durable effects. The drug addresses a significant unmet medical need in a rare disease, and the company has clear next steps for development and reformulation. The only minor caveats are the open-label nature of the study and the historical comparison, but the overall data is very encouraging.

Positives

• SGX945 demonstrated biological efficacy in its Phase 2a study for Behet's Disease, meeting the primary study objective.
• SGX945 showed a 40% improvement in oral ulcers (AUC) at 4 weeks compared to placebo, outperforming apremilast's 37% improvement in its Phase 3 study.
• The efficacy of SGX945 was sustained for 4 weeks post-treatment (32% improvement at Week 8), suggesting a durable response despite being administered only twice weekly for 4 weeks.
• SGX945 was well-tolerated with no treatment-related adverse events, a significant advantage over apremilast which has common side effects like diarrhea, nausea, and headache.
• 7 out of 8 patients reported perceived benefit, including reduced ulcer duration, number, and pain, indicating strong patient satisfaction.
• SGX945 showed potential for treating difficult-to-resolve skin ulcers, as evidenced by the resolution of a punctuated skin ulcer in one patient.
• The drug addresses an unmet medical need in Behet's Disease, particularly for more severe ulcers (genital and skin) for which apremilast is not approved.

Negatives

• The Phase 2a study was open-label, which may introduce bias compared to a placebo-controlled, double-blind study.
• The comparison to apremilast was historical, using data from a separate Phase 3 study, rather than a head-to-head comparative trial.
• While SGX945's effect was durable, apremilast (continuously administered) showed a slightly higher improvement at Week 8 (41% vs. 32% for SGX945).

Risks

• Actual results may differ materially from forward-looking statements due to inherent risks and uncertainties beyond the company's control.
• There is significant uncertainty in developing therapeutics and vaccines, conducting preclinical and clinical trials, obtaining regulatory approvals, and manufacturing products.
• Product development and commercialization efforts may be reduced or discontinued due to difficulties, delays in clinical trials, or lack of progress/positive results from R&D.
• The company may not be able to successfully obtain further funding to support product development and commercialization efforts, including grants and awards.
• Existing grants are subject to performance requirements and may not be maintained.
• The company may not be able to enter into any biodefense procurement contracts with the U.S. Government or other countries.
• Competition from larger and better-financed competitors in the biotechnology industry poses a risk.
• Changes in healthcare practice, third-party reimbursement limitations, and federal/state healthcare reform initiatives could negatively affect the business.
• The U.S. Congress may not pass legislation providing additional funding for the Project BioShield program.
• There is no assurance as to the timing or success of any of the company's clinical/preclinical trials.
• Despite prior positive results, there is no assurance that the second HyBryte (SGX301) Phase 3 clinical trial will be successful or that marketing authorization from the FDA or EMA will be granted.
• No assurance that the company can modify the development path to adequately address FDA's concerns for HyBryte or that the FDA will not require a longer duration comparative study.
• No assurance as to the timing or success of the clinical trials of SGX302 for the treatment of psoriasis.
• Despite observed biologic activity, there is no assurance as to the timing or success of future clinical trials of SGX945 for the treatment of Behet's Disease.
• There is no assurance that RiVax will qualify for a biodefense Priority Review Voucher (PRV) or that prior PRV sales will be indicative of any potential sales price for a RiVax PRV.
• No assurance that the company will receive or continue to receive non-dilutive government funding from grants and contracts.

Future Outlook

Soligenix intends to reformulate SGX945 for home-based subcutaneous injection to enhance its chronic use and maintenance profile. The company plans to engage with health authorities to design a follow-on placebo-controlled Phase 2 study for SGX945 in Behet's Disease. They also aim to expand dusquetide's development into other innate immune-related inflammatory conditions as part of a long-term strategy to enhance the compound's value.

Management Comments

• "The benefit of SGX945 was observed in 7 of 8 patients treated in this study, and many patients also commented on the reduced symptoms they experienced in the weeks following treatment as well, stated Dr. Glen Hatemi, MD, Professor of Medicine, Division of Rheumatology, Department of Internal Medicine and Behets Disease Research Center, Istanbul University and lead investigator in the DUS-AUBD-01 study."
• "As a twice weekly treatment, the durability of the response may indicate a favorable chronic use or maintenance profile for SGX945, particularly if it is available in a self-administered formulation."
• "We are pleased to have demonstrated biological efficacy in our SGX945 Phase 2a trial in aphthous ulcers of Behets Disease, stated Christopher J. Schaber, PhD, President and Chief Executive Officer of Soligenix."
• "Given the role of the innate immune system in ulcers associated with Behets Disease, and the unmet medical need particularly for more severe ulcers such as genital and skin ulcers, we believe that dusquetide may offer significant relief to patients."
• "With these results, we intend to embark on a reformulation of SGX945 to enable home-based treatment, using subcutaneous injection as used for example with weight-loss drugs. We are excited to expand dusquetides development into different innate immune-related inflammatory conditions, such as Behets Disease, as a component of our long-term strategy to enhance the value of this unique compound."

Industry Context

Behet's Disease is a rare, incurable, and chronic inflammatory disorder with a significant unmet medical need, particularly for severe ulcers beyond oral manifestations. The only currently approved drug, apremilast (Otezla), is limited to oral ulcers, requires continuous administration, and is associated with notable side effects and high cost. Soligenix's SGX945, an innate defense regulator, offers a novel mechanism of action and a potentially superior safety profile, positioning it as a promising alternative in a market with limited effective and well-tolerated treatments.

Comparison to Industry Standards

• SGX945's 40% improvement in oral ulcers (AUC) at 4 weeks surpassed apremilast's 37% improvement relative to placebo in its Phase 3 study, indicating superior initial efficacy.
• SGX945 demonstrated sustained efficacy (32% improvement at Week 8) even after treatment cessation at Week 4, suggesting a more durable response compared to apremilast which requires continuous administration for effect (41% improvement at Week 8 with continuous use).
• SGX945 was well-tolerated with no treatment-related adverse events, a significant advantage over apremilast, which commonly causes diarrhea (41%), nausea (19%), and headache (14%).
• Unlike apremilast, which is only approved for oral ulcers, SGX945 showed potential for treating more severe manifestations like skin ulcers, addressing a broader unmet need in Behet's Disease.
• The twice-weekly administration of SGX945, with potential for self-administered subcutaneous formulation, offers a more convenient treatment profile compared to apremilast's continuous oral dosing.

Stakeholder Impact

• **Shareholders**: Positive clinical trial results for a key pipeline asset (SGX945) could increase investor confidence and potentially lead to share price appreciation.
• **Patients with Behet's Disease**: Potential for a new, more effective, and better-tolerated treatment option, especially for severe ulcers, which could significantly improve quality of life.
• **Healthcare Providers**: A new therapeutic option for Behet's Disease that offers advantages in efficacy, safety, and potentially convenience over existing treatments.
• **Employees**: Continued progress in clinical development strengthens the company's position and provides job security and potential for growth.

Next Steps

• Embark on a reformulation of SGX945 to enable home-based treatment via subcutaneous injection.
• Interact with health authorities to design a follow-on placebo-controlled Phase 2 study for SGX945 in Behet's Disease.
• Expand dusquetide's development into different innate immune-related inflammatory conditions.

Key Dates

Recommendation

The filing details highly positive Phase 2a clinical trial results for SGX945 in Behet's Disease, demonstrating biological efficacy, superior initial performance compared to the only approved competitor (apremilast), a significantly better safety profile, and durable effects. This addresses a substantial unmet medical need in a rare disease. The clear path forward for reformulation and further studies, combined with the strong competitive advantages, positions Soligenix favorably for future value creation. The positive data significantly de-risks this asset and suggests strong commercial potential, making it a compelling 'strong buy' for investors seeking exposure to the rare disease biopharmaceutical sector.

Keywords

Behet's Disease, SGX945, dusquetide, Phase 2a clinical trial, biological efficacy, oral ulcers, innate defense regulator, IDR, rare diseases, biopharmaceutical, clinical development, orphan disease, Soligenix, SNGX, apremilast, Otezla, mucocutaneous involvement, subcutaneous injection, drug reformulation